CONCWSIONS: Cyclophosphamide can be extemporaneously prepared in simple syrup or Ora-Plus and stored for at least 2 months under refrigerationwithout signifICant degradation. BACKGROUND: Cyclophosphamide, an alkylatlng agent, Is widely used for Ihe treatment of many adultand pediatric malignancies. The stabil ity of cyclophosphamide In aqueous-and methylcellulose-based oral suspending vehicles is currenUy unknown.
RESULTS: samplesof cyclophosphamide in bothsimple syrup andOra-Plus were stablewhen kept at4 DC for at least 56 days. At room temperature, cyclophosphamide in simple syrup and Ora-Plus had a shelf life of 8 and 3 days, respectively. No changesin color or odor or evidence of microbialgrowth were observed.
T he alkylating agent cyclophosphamide is a widely administered chemotherapeutic drug usedto treata broadspectrum of malignancies.l-' After activation of cyclophosphamide by hepatic enzymes, the active metabolite forms covalent bonds with DNA and proteins, inducing cell death.r" Cyclophosphamide is often administered intravenously as induction therapy.' Significant dose-dependent toxicities, particularly myelosuppression, occur in bothchildren and adults."
Tumor growth is largely supported by angiogenesis. s High-dosecyclophosphamide has been shown to have an anti-angiogenic effectin tumorcells," However, administering continuous low-dose oral cyclophosphamide (ie,metronomic therapy) also prevents angiogenesis, with less risk of toxicity.":" Metronomic cyclophosphamide delayed progression of prostate cancer, breast cancer, and erythroleukemia in mousemodels, with minimal toxicity. 12, 13 In adults withmetastatic breast cancer, Colleoni andcolleagues found that metronomically administered cyclophosphamide achieves significant long-term disease stability with minimal leukopenia,"In pediatric studies, low-dose metronomiccyclophosphamide was well tolerated and showed promising response with tlnle toxicity in patients with heavily pretreated solid tumors. 14 ,15 Due to daily drug administration during maintenance therapy, it is preferable to give cyclophosphamide orally, Author information provided at end of text. and in the case of young children, to administer it as an oral suspension. A previous oral suspension of cyclophosphamide was prepared in aromatic elixir, USP; however, this vehicle is no longercommercially available. Although it was reported that cyclophosphamide is stable for at least 2 weeks at 5°C in aromatic elixir, USP, its stability in modern suspending agents is unknown," In this study,we
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The AnnalsofPharmacotherapy • 2010 February, Volume 44 • 295 validated and implemented a stability-indicating high-performance liquid chromatography (HPLC) method to determine the stability of cyclophosphamide over 56 days in both simple syrup and Ora-Plus.
Methods

CHEMICALS AND REAGENTS
Cyclophosphamide used for the preparation of standards and quality control samples and ifosfamide used as the internal standard were supplied by Sigma-Aldrich (St. Louis, MO). Vials of cyclophosphamide 2 g injection, USP, and NaCl 0.9% used to prepare the suspensions for stability studies were supplied by Baxter (Deerfield, IL). Simple syrup and Ora-Plus were supplied by Humco (Texarkana, TX) and Paddock Laboratories (Minneapolis, MN), respectively. HPLC grade acetonitrile and methanol were purchased from Burdick & Jackson (Muskegon, MI). Sodium phosphate monobasic monohydrate, phosphoric acid, and sodium hydroxide were obtained from Fisher Scientific (Fairlawn, NJ). All water was distilled, deionized, and purified with a Millipore Milli-Q UV plus and Ultra-Pure Water System (Tokyo, Japan).
EQUIPMENT AND CHROMATOGRAPHIC CONDITIONS
The HPLC system consisted of a Shimadzu (Kyoto, Japan) LC-20AD pump, a Shimadzu SPD-IOAVP UV-VIS detector with a detection wavelength of 190 nm, and a Shimadzu SIL-IOADVP autoinjector set to 4 ·C with an injection volume of 50 flL. Chromatographic data were analyzed using Shimadzu Class-VP Integrating Software v. 7.3. Our preliminary conditions were based on previously reported methods.":" All chromatographic separations were obtained using a Phenomenex Luna, 5-flm, C18, 100A, 125 x 4-mm column (Torrance, CA) with a Phenomenex Security Guard, C 18,4 x 2.0-mm guard column. Analytes were eluted using an acetonitrile-phosphate buffer (21:79) mobile phase flowing at 1.0 mL/min. The 0.2-M sodium phosphate monobasic monohydrate mobile phase buffer, prepared in distilled, deionized water (DDH20), was adjusted to pH 4.0 with phosphoric acid and sodium hydroxide using an Orion 250A pH meter (Beverly, MA). The phosphate buffer was vacuum filtered through a 0.2flm PALL membrane (Port Washington, NY).
PREPARATION OF STOCK AND WORKING SOLUTIONS
A 200-mg/mL stock solution was prepared by dissolving cyclophosphamide powder in 80% methanol/20% DDH 20. Aliquots of the stock solution were stored in 4-mL glass amber vials at -20 ·C. Appropriate dilutions of the stock solution were made in 80% methanol/20% DDH 20 to obtain working stock solutions of 10 and 40 mg/mL, which were also stored at -20 ·C. A l00-mg/mL internal standard stock solution was prepared by dissolving ifosfamide in 80% methanol/20% DDH 20. Aliquots of the internal standard stock solution were stored in 4-mL glass amber vials at -20 ·C. A dilution of the internal standard stock solution was made in 80% methanoV20% DDH 20 to obtain an internal standard working stock solution of 15 mg/ml., and these stocks were also stored at -20 ·C.
CALIBRATION CURVES, SAMPLE PREPARATION, AND
QUALITY CONTROLS
Simple syrup and Ora-Plus calibration standards were prepared by adding cyclophosphamide working stock solutions to either syrup suspension to achieve the following concentrations: 5,7,10,15, and 20 mg/mL.lfosfamide internal standard working stock solution was added to each standard to create a final concentration of 1.5 mg/mL. The lower limit of quantification of cyclophosphamide in simple syrup and Ora-Plus was defined as the first calibration curve standard, which had a signal-to-noise ratio <5. Quality control samples were prepared by adding cyclophosphamide working stock solutions to simple syrup and Ora-Plus to obtain final concentrations of 8, 12, and 18 mg/mL. Before all analytic runs, all standards, quality controls, and cyclophosphamide stability samples were diluted to a 20x final dilution in 20% methanol/80% DDH 20.1\vo calibration curves of both simple syrup and Ora-Plus were obtained by performing linear regression on the analyte/internal standard peak height ratio and the analyte/intemal standard quantity ratio. Prior to measurement of each weekly stability sample, 3 quality controls (low, middle, and high) were prepared and analyzed to ensure that values were accurate within 10% of the nominal value. If controls were not within 10% of their nominal value, a new calibration curve was prepared and analyzed.
METHOD VALIDATION
Intradayand InterdayPrecisionand Accuracy
Intraday precision (expressed as % coefficient of variation [CV)) and accuracy was evaluated by preparing and analyzing 10 low (8 mg/mL) and 10 high (18 mg/mL) replicates within 1 day. Interday precision and accuracy was evaluated by preparing and analyzing 3 low (8 mg/mL),3 middle (12 mg/mL), and 3 high (18 mg/mL) replicates for 4 consecutive days. The criteria for acceptability of the method included accuracies within 10% of the nominal value and precisions with < 10% CV.
Specificity, Conversion, and Carry-Over
No peaks co-eluted with cyclophosphamide or ifosfamide in either simple syrup or Ora-Plus. To assess conver-sion to degradation products and possible interference, neat aliquots of the middle quality control were prepared in 20% methanol/80% DDH 2 0 without internal standard. These aliquots were heated at 45°C and periodically analyzed in order to observe the appearance of secondary peaks in the chromatogram as well as peak shifting and asymmetry. To assess carry-over, cyclophosphamide samples (20 mglmL) in simple syrup and Ora-Plus were injected and followed by one wash run to determine whether any residual cyclophosphamide would be detected in the wash.
CYCLOPHOSPHAMIDE STABILITY EXPERIMENTS
Cyclophosphamide samples were prepared in the Central Pharmacy at St. Jude Children's Research Hospital in a manner consistent with how they are prepared for patients. Vials of cyclophosphamide 2 g injection, USP, were reconstituted with 100 mL of NaCI 0.9% to a concentration of 20 mglmL prior to compounding. This cyclophosphamide injectable solution was then mixed in a I: 1 ratio with either simple syrup or Ora-Plus for a final concentration of 10 mg/mL. Aliquots of 2.4 mL were added to 3-mL amber polypropylene oral dispensing syringes (Becton Dickinson Co., Franklin Lakes, NJ). One syringe of each suspension was stored in a plastic bag inside a closed box in a 4°C (range 3.8-4.2 "C) cold room. Another syringe of each suspension was stored in a plastic bag in a drawer at approximately 22°C (range 21.3-22.5 "C), Cyclophosphamide concentrations in all samples were analyzed immediately after compounding and after 3, 7,14,21,28,35,42,49, and 56 days. On each day of the stability study, 3 replicates of each sample were spiked with internal standard and diluted as outlined in the calibration curve and method validation sections; they were also assayed in triplicate. The color was examined under normal fluorescent lighting, the odor was examined, and an aliquot of the suspension was observed under a light microscope for evidence of microbial growth. Linear regression of all concentration data was performed using GraphPad Prism version 5.02 for Windows (Graph-Pad Software, San Diego, CA). Samples were considered stable if the 95% lower confidence limit of the estimated regression line was within 10% of the initial concentration.
Results
CYCLOPHOSPHAMIDE ASSAY DEVELOPMENT
Because sample extraction was not necessary, little optimization was performed to improve experimental conditions. As shown in Figure lA , the chromatogram of blank simple syrup shows a single peak at 4.5 minutes, whereas 2 peaks, eluting at 5.9 and 9.4 minutes, are present in the blank Ora-Plus chromatogram ( Figure IC) . The percent acetonitrile in the mobile phase was adjusted to ensure adequate resolution between the analyte and the internal stan-Stability ofCyclophosphamide in Extemporaneous Oral Suspensions dard peaks and between the analyte and the late eluting peak in Ora-Plus ( Figure ID) , and secondly to minimize the run time. With our final chromatographic conditions, the resolution (R) value was~1.09 between these 2 peaks. In simple syrup, the retention times of cyclophosphamide and ifosfamide were 8.4 minutes and 7.5 minutes, respectively, with a total run time of 9.5 minutes ( Figure IB) . Retention times were similar with Ora-Plus, except the total run time was 10 minutes ( Figure 10 ).
CYCLOPHOSPHAMIDE ASSAY VALIDATION
Simple syrup calibration curves for cyclophosphamide were linear over a concentration range of 5-20 mg/ml., with correlation coefficient (r2) equal to 0.994 (y = 1.5646x -1.1006). The Ora-Plus calibration curve for cyclophosphamide was linear over a concentration range of 5-20 mg/mL with an r2 value of 0.999 (y =1.7125x -0.8341).
The intraday precision (CV) in simple syrup was s3.4%, with an accuracy (change from nominal value) of s5.4%; in Ora-Plus the intraday precision was s3.7%, with an accuracy of s3.2%. As shown in Table I , interday precision of the cyclophosphamide assay in both simple syrup and Ora-Plus was within 5.5% and accuracy was within 4.3%. The lower limit of quantification was 5 mg/rnl., which was acceptable for the concentration range over which samples were measured. Although lower concentrations were detected on the column, 5 mg/mL was found to be the lowest concentration that fit well with the calibration curve, as a slight deviation from linearity was noted below this concentration. No secondary peaks indicating detectable degradation products appeared in the chromatograms analyzed during the conversion study. Furthermore, the cyclophosphamide peak did not shift or lose symmetry throughout the study, implying that possible degradation products did not co-elute with the cyclophosphamide peak. No residual peaks appeared in carryover studies.
STABILITY OF CYCLOPHOSPHAMIDE IN ORAL
SUSPENDING VEHICLES
Cyclophosphamide suspended in simple syrup and stored at 4°C retained its concentration within 96% of the baseline value at 56 days after compounding (Figure 2A , Table 2 ). Cyclophosphamide suspended in Ora-Plus and stored at 4°C retained its concentration within 98% of the baseline value at 56 days after compounding ( Figure 2B , Table 2 ). Because there was nearly no degradation within 56 days, linear regression analysis could not be used to assess when the cyclophosphamide would be degraded by 10%. Based on the linear regression analysis of cyclophosphamide concentrations expressed as a percent of the initial values, cyclophosphamide in simple syrup is degraded by 10% after 10.6 days (90% CI 8.7 to 12.2) and in Ora-
theannals.com
The Plus is degraded by 10%after6.0 days (90% CI 3.4 to 8.2) when stored at 22°C (Figure 2 ). Upon visual observation with a light microscope, no microbial growthwas seen.No color or odor changeoccurred in any samples.
Discussion
The HPLC assay that we developed and validated for measuring cyclophosphamide in suspending agents was specific, precise,and accurate. Our preliminary conditions for the HPLC method were basedon several previous studies, which used a mobile phasecomprising 20% acetonitrile and 80% phosphate buffer.":" Wefound thatwithour initial assay conditions, substances in Ora-Plus causedpeaks that overlapped with the cyclophosphamide and ifosfamide peaks.Changing these conditions yielded acceptable resolution of cyclophosphamide and ifosfamide peaks. For assays of plasmacyclophosphamide, we have useda Phenomenex GeminiCl8 100 x 2 mm column," For this stability assay, we chose a Phenomenex Luna Cl8 125 x 4 mm column, whichprovided better resolution of peaks due to greater column length and volume. The forced-degradation experiment showsthat thisassay is stability-indicating.
Low-dose cyclophosphamide is increasingly beingused for maintenance therapy in children withsolidtumors. 14.1S ,20
Stability ofCyclophosphamide in Extemporaneous Oral Suspensions
Daily administration of maintenance therapy necessitates that thedrugbe administered orally. Although cyclophosphamide is available in tablet form,an oral suspension is a betteroptionfor infants and youngchildren. Sincethereare no commercially available pediatric formulations of cyclophosphamide, suspensions have beenextemporaneously prepared inaromatic elixir. Because aromatic elixiris alcohol-based, it is less palatable to children. It was shown that suspensions of cyclophosphamide in aromatic elixir were stable for 2 weeks at 5°C. 16 Although it is likely stable beyond this time, becausethere were no data to supportthis, pharmacists would prepare only a 2-week supplyat one time.
Aromatic elixir is no longer commercially available. Thus, a new suspending agent is needed for administration of oral cyclophosphamide to youngchildren.We chose to examine cyclophosphamide in 2 suspending agents: simple syrup and Ora-Plus. Ora-Plus has the advantage of containing preservatives, which reduce the possibility of microbial contamination. Cyclophosphamide has high solubility in neutral and acidic aqueous solutions,and thus it was possible to compound a lO-mg/mL solution.
Cyclophosphamide was stable at 4°C in both simple syrupand Ora-Plus for 56 days. At day56, theconcentration had notchanged significantly from the starting concentration of 10mg/mL. Thus,it is likely to be stable for longer, butwe theannals.com TheAnnalsofPharmacotherapy • 2010February, Volume 44 • 299 did not examine later time points. We did not examine whether the rateof degradation was affected by light; therefore,it is recommended that the oralsyringes be kept in the dark.With this information, pharmacists can prepare a supplyof oralcyclophosphamide suspension for two28-daycycles at one time, compared to the 2-week supply that was prepared previously. This is more convenientfor patients' families and moretime-andcost-efficient for thepharmacy. When stored at room temperature, cyclophosphamide in the oral suspensions degraded by' 10% much more rapidly than at 4 ·C . The lower 95% confidence limit of when the concentration reached 90% of the initial value was 8.7 days for simplesyrup and 3.4 days for Ora-Plus.We therefore consider the shelf life of thesesuspensions to be 8 and 3 days, respectively. This is similar to what was reported for a parenteral formulation of cyclophosphamide in infusion fluids at 20-22 ·C. 21 Cyclophosphamide was reported to be degraded by >80% after 4 days at room temperature when mixed with mesna in dextrose 5% in polyethylene infusion bags," Although it is recommendedthat the suspension be stored in the refrigerator, if a syringe is left out for a day, it should not result in significant loss of potency. Due to possible photodegradation, we recommendthe use of amber syringes. This study did not examine what the degradation products of cyclophosphamide are in these oral suspensions. However, a previous study showed that in buffered aqueous solutions, multiple pH-dependenthydrolysis products wereobserved, none of whichhad antitumor activity." We expect that simple syrup and Ora-Plus solutions are in the pH range in which there is little effect of pH on the rate of degradation (pH 3.4-8.6), although the rate of degradation is increased at lower pHs. 23 During the time that aromatic elixirhas beenunavailable, somepediatric oncology sites havebeenadministering intravenouscyclophosphamide 20 mg/mL via oral syringes to young children. Dispensing an injectable medication without modifying it into an oral formulation could lead to wrong route of administration if thecontainer is notproperly labeled as beingfor oral use only. Cyclophosphamide for injection would also be less palatable than a properlycompounded oral formulation with simplesyrupor Ora-Plus. This could lead families to diluteit in beverages or vehicles of varying pH with potential differences in bioavailability or stability. Simple syrup and Ora-Plus also contain preservatives to help prevent microbial growth during storage. Dosages of oralcyclophosphamide are lowenough thatthe lO-mg/mL concentration results in a dose volume that is reasonable for infants and young children to swallow. A lO-mg/mL concentration is also easy to accurately measurein oral syringes, which could result infewer dosing errors. This study has shown that simple syrup and Ora-Plus are suitable for the extemporaneous preparation of suspensions of parenteral cyclophosphamide. Thus,we recommend using these suspending agents in which cyclophosphamide is now documented to be stable for 8 weeks, compared to a documented stability of only2 weeks in aromatic elixir. The pharmacokinetics of cyclophosphamide whencompounded insimple syrup are nowbeing examined in a clinical study of infants andyoung children with brain tumors. and the American Lebanese Syrian Associated Charities (ALSAC).
